{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:50:12Z","timestamp":1792047012641,"version":"4.4.0"},"posted":{"date-parts":[[2026,4,1]]},"group-title":"In Review","reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,17]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background.<\/bold>\n                  Pain drives disability and medication use in autoimmune rheumatic diseases (ARDs), even when inflammation is controlled. The extent of pain-related polypharmacy across ARDs and chronic overlapping pain conditions (COPCs) remains poorly characterized. We aimed to quantify first-year pain medication burden following ARD diagnosis and examine variations by disease, COPC status, and time.\n                  <bold>Methods.<\/bold>\n                  Using the Merative MarketScan Commercial Claims database, we identified adults newly diagnosed with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Sj\u00f6gren\u2019s disease, or systemic sclerosis (2008\u20132021). We analyzed pain-related medications across ten pharmacologic categories during the first year post-diagnosis. Polypharmacy measures included distinct medication counts, medication categories, \u2265\u20095 and \u2265\u200910 medication thresholds, and the Medication Quantification Scale.\n                  <bold>Findings.<\/bold>\n                  Among 149,742 adults with newly diagnosed ARDs, 57.6% had at least one COPC. During the first year after diagnosis, patients filled a mean of 9.0 distinct pain medications and 47.9% met criteria for \u2265\u20095 medications; 30.5% met criteria for \u2265\u200910 medications. Ankylosing spondylitis demonstrated the highest medication burden (mean 11.6 medications; 57.5% with \u2265\u20095 medications; 37.9% with \u2265\u200910 medications). Patients with fibromyalgia had consistently higher medication burden across ARDs and were the only COPC group in whom prescribing increased after 2015. Overall medication burden rose from 2008 to 2014\u20132015 and declined thereafter; however, absolute levels remained high.\n                  <bold>Interpretation.<\/bold>\n                  Pain-related polypharmacy is common early after ARD diagnosis and varies substantially by disease and pain phenotype. Despite modest declines after 2015, medication burden remains high, underscoring the need for phenotype-informed, nonpharmacologic, and deprescribing strategies in rheumatology.\n                  <bold>Funding.<\/bold>\n                  NIAMS (K01AR079039).\n                <\/p>","DOI":"10.21203\/rs.3.rs-9152435\/v1","type":"posted-content","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:25:19Z","timestamp":1775028319000},"source":"Crossref","is-referenced-by-count":0,"title":["High Burden and Phenotype-Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 15-Year Real-World Analysis"],"prefix":"10.21203","author":[{"given":"Di","family":"Lu","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Cunanan","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cragun","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Vuong","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarius","family":"Donneyong","sequence":"additional","affiliation":[{"name":"The Ohio State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weisman","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Baker","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Irani","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titilola","family":"Falasinnu","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","author":"Abend AH","year":"2024","unstructured":"Abend AH, He I, Bahroos N, et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J Clin Invest. 2024;135. 10.1172\/JCI178722.","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"101970","DOI":"10.1016\/j.berh.2024.101970","article-title":"Inflammatory or non-inflammatory pain in inflammatory arthritis - How to differentiate it?","volume":"38","author":"Sarzi-Puttini P","year":"2024","unstructured":"Sarzi-Puttini P, Pellegrino G, Giorgi V, et al. Inflammatory or non-inflammatory pain in inflammatory arthritis - How to differentiate it? Best Pract Res Clin Rheumatol. 2024;38:101970.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/ard-2023-225414","article-title":"Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain","volume":"83","author":"Baerwald C","year":"2024","unstructured":"Baerwald C, Stemmler E, Gn\u00fcchtel S, et al. Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain. Ann Rheum Dis. 2024;83:1381\u20138.","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar3353","article-title":"Pain persists in DAS28 rheumatoid arthritis remission but not in ACR\/EULAR remission: a longitudinal observational study","volume":"13","author":"Lee YC","year":"2011","unstructured":"Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR\/EULAR remission: a longitudinal observational study. Arthritis Res Ther. 2011;13:R83.","journal-title":"Arthritis Res Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis I","year":"2025","unstructured":"Parodis I, Haugli-Stephens T, Dominicus A, Eek D, Sj\u00f6wall C. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up. Rheumatology (Oxford). 2025;64:639\u201347.","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/acr2.11488","article-title":"The Problem of Pain in Rheumatology: Clinical Profiles Associated With Concomitant Diagnoses With Chronic Overlapping Pain Conditions","volume":"4","author":"Falasinnu T","year":"2022","unstructured":"Falasinnu T, Nguyen T, Jiang TE, et al. The Problem of Pain in Rheumatology: Clinical Profiles Associated With Concomitant Diagnoses With Chronic Overlapping Pain Conditions. ACR Open Rheumatol. 2022;4:890\u20136.","journal-title":"ACR Open Rheumatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41582-024-00966-8","article-title":"Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms","volume":"20","author":"Kaplan CM","year":"2024","unstructured":"Kaplan CM, Kelleher E, Irani A, Schrepf A, Clauw DJ, Harte SE. Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms. Nat Rev Neurol. 2024;20:347\u201363.","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/keac671","article-title":"Non-inflammatory pain in inflammatory arthritis","volume":"62","author":"Das D","year":"2023","unstructured":"Das D, Choy E. Non-inflammatory pain in inflammatory arthritis. Rheumatology (Oxford). 2023;62:2360\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5114\/reum\/189779","article-title":"The problem of residual pain in the assessment of rheumatoid arthritis activity","volume":"62","author":"Motyl G","year":"2024","unstructured":"Motyl G, Krupka WM, Ma\u015bli\u0144ska M. The problem of residual pain in the assessment of rheumatoid arthritis activity. Reumatologia. 2024;62:176\u201386.","journal-title":"Reumatologia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/art.43152","article-title":"Nociplasticity: A Proposed Concept to Understand the Symptomatology of Systemic Lupus Erythematosus","volume":"77","author":"Pisetsky DS","year":"2025","unstructured":"Pisetsky DS, Rogers JL, Eudy AM, Martucci KT, Ji R-R, Lipsky PE. Nociplasticity: A Proposed Concept to Understand the Symptomatology of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025;77:966\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/acr.25104","article-title":"Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review","volume":"75","author":"Murphy AE","year":"2023","unstructured":"Murphy AE, Minhas D, Clauw DJ, Lee YC. Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review. Arthritis Care Res (Hoboken). 2023;75:2215\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jpain.2023.01.018","article-title":"Polygenic Contributions to Chronic Overlapping Pain Conditions in a Large Electronic Health Record Sample","volume":"24","author":"Schirle L","year":"2023","unstructured":"Schirle L, Samuels DC, Faucon A, Cox NJ, Bruehl S. Polygenic Contributions to Chronic Overlapping Pain Conditions in a Large Electronic Health Record Sample. J Pain. 2023;24:1056\u201368.","journal-title":"J Pain"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2017-212662","article-title":"EULAR recommendations for the health professional\u2019s approach to pain management in inflammatory arthritis and osteoarthritis","volume":"77","author":"Geenen R","year":"2018","unstructured":"Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional\u2019s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:797\u2013807.","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.27.23291959","author":"Johnston KJA","year":"2024","unstructured":"Johnston KJA, Signer R, Huckins LM. Chronic Overlapping Pain Conditions and Nociplastic Pain. medRxiv. 2024; published online May 8. 10.1101\/2023.06.27.23291959"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"T93","DOI":"10.1016\/j.jpain.2016.06.002","article-title":"Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification","volume":"17","author":"Maixner W","year":"2016","unstructured":"Maixner W, Fillingim RB, Williams DA, Smith SB, Slade GD. Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification. J Pain. 2016;17:T93\u2013107.","journal-title":"J Pain"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e70116","DOI":"10.1002\/acr2.70116","article-title":"Visualizing Real-World Pain Treatment Pathways in Chronic Disease: A Sequence-Based Analysis of Polypharmacy in Systemic Lupus Erythematosus","volume":"7","author":"Le N","year":"2025","unstructured":"Le N, Kenney MO, Walker A, et al. Visualizing Real-World Pain Treatment Pathways in Chronic Disease: A Sequence-Based Analysis of Polypharmacy in Systemic Lupus Erythematosus. ACR Open Rheumatol. 2025;7:e70116.","journal-title":"ACR Open Rheumatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1016\/S2665-9913(24)00120-6","article-title":"Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study","volume":"6","author":"Falasinnu T","year":"2024","unstructured":"Falasinnu T, Lu D, Baker MC. Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study. Lancet Rheumatol. 2024;6:e518\u201327.","journal-title":"Lancet Rheumatol"},{"key":"ref18","first-page":"39","article-title":"Narcotics in rheumatology","volume":"6","author":"Tehrani M","year":"2013","unstructured":"Tehrani M, Aguiar M, Katz JD. Narcotics in rheumatology. Health Serv Insights. 2013;6:39\u201345.","journal-title":"Health Serv Insights"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1759720X11408999","article-title":"Management of chronic pain in the rheumatic diseases with insights for the clinician","volume":"3","author":"Fitzcharles M-A","year":"2011","unstructured":"Fitzcharles M-A, Shir Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis. 2011;3:179\u201390.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.24545","article-title":"Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population","volume":"61","author":"Li T","year":"2009","unstructured":"Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009;61:755\u201363.","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e027495","DOI":"10.1136\/bmjopen-2018-027495","article-title":"Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study","volume":"9","author":"Chen SK","year":"2019","unstructured":"Chen SK, Feldman CH, Brill G, Lee YC, Desai RJ, Kim SC. Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. BMJ Open. 2019;9:e027495.","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.sapharm.2024.05.006","article-title":"A comparative analysis of medication counting methods to assess polypharmacy in medico-administrative databases","volume":"20","author":"Gagnon M-E","year":"2024","unstructured":"Gagnon M-E, M\u00e9sidor M, Simard M, et al. A comparative analysis of medication counting methods to assess polypharmacy in medico-administrative databases. Res Social Adm Pharm. 2024;20:905\u201310.","journal-title":"Res Social Adm Pharm"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jpain.2023.09.010","article-title":"The Medication Quantification Scale 4.0: An Updated Index Based on Prescribers\u2019 Perceptions of the Risk Associated With Chronic Pain Medications","volume":"25","author":"Clifford-Faug\u00e8re G","year":"2024","unstructured":"De Clifford-Faug\u00e8re G, Nguena Nguefack HL, Godbout-Parent M, et al. The Medication Quantification Scale 4.0: An Updated Index Based on Prescribers\u2019 Perceptions of the Risk Associated With Chronic Pain Medications. J Pain. 2024;25:508\u201321.","journal-title":"J Pain"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpain.2005.01.350","article-title":"Medication Quantification Scale Version III: update in medication classes and revised detriment weights by survey of American Pain Society Physicians","volume":"6","author":"Harden RN","year":"2005","unstructured":"Harden RN, Weinland SR, Remble TA, et al. Medication Quantification Scale Version III: update in medication classes and revised detriment weights by survey of American Pain Society Physicians. J Pain. 2005;6:364\u201371.","journal-title":"J Pain"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/pme.12586","article-title":"Polypharmacy and chronic pain: harm exposure is not all about the opioids","volume":"16","author":"Giummarra MJ","year":"2015","unstructured":"Giummarra MJ, Gibson SJ, Allen AR, Pichler AS, Arnold CA. Polypharmacy and chronic pain: harm exposure is not all about the opioids. Pain Med. 2015;16:472\u20139.","journal-title":"Pain Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ner.13524","article-title":"Cross-Country Differences in Pain Medication Before and After Spinal Cord Stimulation: A Pooled Analysis of Individual Patient Data From Two Prospective Studies in the United Kingdom and Belgium","volume":"26","author":"Goudman L","year":"2023","unstructured":"Goudman L, Duarte RV, De Smedt A, Copley S, Eldabe S, Moens M. Cross-Country Differences in Pain Medication Before and After Spinal Cord Stimulation: A Pooled Analysis of Individual Patient Data From Two Prospective Studies in the United Kingdom and Belgium. Neuromodulation. 2023;26:215\u201323.","journal-title":"Neuromodulation"},{"key":"ref27","author":"Dick BD","year":"2011","unstructured":"Dick BD, Rashiq S, Verrier MJ, Ohinmaa A, Zhang J, Symptom Burden. Medication Detriment, and Support for the Use of the 15D Health-Related Quality of Life Instrument in a Chronic Pain Clinic Population. Pain Res Treat 2011; 2011: 809071."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention\u2019s 2016 Opioid Guideline","volume":"169","author":"Bohnert ASB","year":"2018","unstructured":"Bohnert ASB, Guy GP Jr, Losby JL. Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention\u2019s 2016 Opioid Guideline. Ann Intern Med. 2018;169:367\u201375.","journal-title":"Ann Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00296-025-05804-8","article-title":"The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study","volume":"45","author":"Berthelot W","year":"2025","unstructured":"Berthelot W, Sirois C, Julien A-S, et al. The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study. Rheumatol Int. 2025;45:44.","journal-title":"Rheumatol Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00296-016-3568-2","article-title":"Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study","volume":"36","author":"Rivera J","year":"2016","unstructured":"Rivera J, Vallejo MA. Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study. Rheumatol Int. 2016;36:1691\u20139.","journal-title":"Rheumatol Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/rmdopen-2024-004232","article-title":"Machine learning identifies risk factors associated with long-term opioid use in fibromyalgia patients newly initiated on an opioid","author":"Ram\u00edrez Medina CR","year":"2024","unstructured":"Ram\u00edrez Medina CR, Feng M, Huang Y-T, Jenkins DA, Jani M. Machine learning identifies risk factors associated with long-term opioid use in fibromyalgia patients newly initiated on an opioid. RMD Open. 2024;10. 10.1136\/rmdopen-2024-004232.","journal-title":"RMD Open"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinthera.2013.02.003","article-title":"Geographic variation of chronic opioid use in fibromyalgia","volume":"35","author":"Painter JT","year":"2013","unstructured":"Painter JT, Crofford LJ, Talbert J. Geographic variation of chronic opioid use in fibromyalgia. Clin Ther. 2013;35:303\u201311.","journal-title":"Clin Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/medsci13010032","article-title":"State-of-the-Art Review on the Treatment of Axial Spondyloarthritis","author":"Kaltsonoudis E","year":"2025","unstructured":"Kaltsonoudis E, Karagianni P, Memi T, Pelechas E. State-of-the-Art Review on the Treatment of Axial Spondyloarthritis. Med Sci (Basel). 2025;13. 10.3390\/medsci13010032.","journal-title":"Med Sci (Basel)"},{"key":"ref35","unstructured":"Axial Spondyloarthritis. https:\/\/rheumatology.org\/patients\/axial-spondyloarthritis (accessed Feb 12, 2026)."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.130559","article-title":"Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis","volume":"69","author":"Braun J","year":"2010","unstructured":"Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Ann Rheum Dis. 2010;69:1264\u20138.","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3899\/jrheum.170630","article-title":"Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort","volume":"45","author":"Dau JD","year":"2018","unstructured":"Dau JD, Lee M, Ward MM, et al. Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. J Rheumatol. 2018;45:188\u201394.","journal-title":"J Rheumatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/acr.23301","article-title":"Rheumatoid Arthritis Patients\u2019 Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens","volume":"70","author":"Shaw Y","year":"2018","unstructured":"Shaw Y, Metes ID, Michaud K, et al. Rheumatoid Arthritis Patients\u2019 Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. Arthritis Care Res (Hoboken). 2018;70:533\u201341.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-019-0070-y","article-title":"Living a normal life\u2019: a qualitative study of patients\u2019 views of medication withdrawal in rheumatoid arthritis","volume":"3","author":"Baker KF","year":"2019","unstructured":"Baker KF, Isaacs JD, Thompson B. Living a normal life\u2019: a qualitative study of patients\u2019 views of medication withdrawal in rheumatoid arthritis. BMC Rheumatol. 2019;3:2.","journal-title":"BMC Rheumatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e70066","DOI":"10.1002\/acr2.70066","article-title":"Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study","volume":"7","author":"Benamar S","year":"2025","unstructured":"Benamar S, Lukas C, Daien C, et al. Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study. ACR Open Rheumatol. 2025;7:e70066.","journal-title":"ACR Open Rheumatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"101942","DOI":"10.1016\/j.berh.2024.101942","article-title":"Pain mechanisms for the practicing rheumatologist","volume":"38","author":"Minhas D","year":"2024","unstructured":"Minhas D. Pain mechanisms for the practicing rheumatologist. Best Pract Res Clin Rheumatol. 2024;38:101942.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"rkae128","DOI":"10.1093\/rap\/rkae128","article-title":"Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope","volume":"8","author":"Scott IC","year":"2024","unstructured":"Scott IC, Babatunde O, Barker C, et al. Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope. Rheumatol Adv Pract. 2024;8:rkae128.","journal-title":"Rheumatol Adv Pract"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/acr.20005","article-title":"Report of the American College of Rheumatology Pain Management Task Force","volume":"62","author":"American College of Rheumatology Pain Management Task Force","year":"2010","unstructured":"American College of Rheumatology Pain Management Task Force. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res (Hoboken). 2010;62:590\u20139.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9152435\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9152435\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:43:20Z","timestamp":1792046600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9152435\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":43,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9152435\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,4,1]]},"subtype":"preprint"}}